Buy IBRX by Apr 20, 2026.

I’m doing some research on this stock, seems like it could be a moonshot or burnout stock. What y’all say? ImmunityBio (NASDAQ: IBRX) is a small/mid-cap biotech focused on cancer immunotherapy. It just received FDA-approval for a bladder cancer drug ANKTIVA. ImmunityBio is trying to train/boost the immune system (especially NK cells + T cells) to fight cancer more effectively and for longer duration. Their flagship product is ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 receptor agonist designed to activate immune …